CapForce IBD Breakout Opportunities ETF
Limited financial coverage for BOUT.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
Price Chart
About the company
The fund normally invests at least 80% of its net assets (including borrowings for investment purposes) in the equity securities that comprise the index. The index seeks to provide opportunistic investment exposure to those stocks with the potential to "break out," or experience a period of sustained price growth beyond the stock’s recent “resistance level,” with consideration for various market conditions. The fund is non-diversified.
- CEO
- Mark MacArthur
- IPO
- 2018
- HQ
- Valencia, CA, US
Get TickerSpark's AI analysis on BOUT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $16.28M
- Div Yield
- 0.28%
- 52W High
- $49.41
- 52W Low
- $35.05
- 50D MA
- $46.71
- 200D MA
- $41.90
- Beta
- 1.04
- RSI (14)
- 33
- Avg Volume
- 2.14K
No earnings-call transcripts are available for BOUT yet.
- Free Float
- 0.0%
- Shares Outstanding
- 370.78K
- Float Shares
- 0
of shares held by institutions
16 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Benjamin F. Edwards & Company, Inc. | 308 | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 28, 11 | Cuison Gilbert Adrias | sell | 154,871 |
| Jun 28, 11 | Cuison Gilbert Adrias | sell | 154,871 |
| Apr 7, 11 | Cuison Gilbert Adrias | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BOUT coverage
Recent articles, reports, and earnings notes.
No research on BOUT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BOUT report →Capital-FORCE Welcomes IBD® 50 (FFTY) and IBD® Breakout Opportunities (BOUT) ETFs to New Rules-Based ETF Platform
businesswire.com · Apr 29
Capital-FORCE Enters ETF Market with Acquisition of Innovator IBD® 50 (FFTY) and IBD® Breakout Opportunities (BOUT) ETFs
businesswire.com · Apr 17
Innovator Announces Results of Special Meeting of Shareholders Relating to the Reorganizations of Innovator IBD® Breakout Opportunities ETF and Innovator IBD® 50 ETF
globenewswire.com · Apr 10
Innovator IBD Breakout Opportunities ETF (NYSEARCA:BOUT) Stock Price Up 0.8% – Here’s Why
defenseworld.net · Feb 12
Selected ETFs To Watch In 2025
seekingalpha.com · Jan 31
S&P 500 1%+ Gaps Higher
seekingalpha.com · May 3
Rock-Solid Demand Goes Beyond AI Stocks Like Nvidia. Here's Proof.
investors.com · Mar 13
Chicken Wing King Hits All-Time High Amid Strong Expansion
investors.com · Apr 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.